Albany Molecular Research has signed a definitive agreement to be acquired by affiliates of The Carlyle Group and GTCR for $922M. AMRI is a global contract research and manufacturing organization with locations in North America, Europe and Asia. Its key business segments include Discovery and Development Services (DDS), Active Pharmaceutical Ingredients (API), Drug Product (DP), and Fine Chemicals (FC). William Marth, president and chief executive officer, AMRI, said, “This transaction ...